Prevalence of hereditary antithrombin mutations is higher than estimated in patients with thrombotic events

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 4, 2013, Pages 444-448

  Fischer, Ronald ^a   Sachs, Ulrich J ^b   Heidinger, Kathrin S ^a,b   Eisenburger, Dominik ^a   Kemkes Matthes, Bettina ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

antithrombin deficiency; antithrombin mutation; thromboembolism; thrombophilia

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 8; D DIMER; FIBRINOGEN; HOMOCYSTEINE; LIPOPROTEIN A; LOW MOLECULAR WEIGHT HEPARIN;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; POPULATION; PREVALENCE; PRIORITY JOURNAL; THROMBOEMBOLISM;

ADOLESCENT; ADULT; ANTITHROMBIN III; CASE-CONTROL STUDIES; EXONS; FEMALE; HETEROZYGOTE; HUMANS; MALE; MUTATION, MISSENSE; SEQUENCE ANALYSIS, DNA; THROMBOEMBOLISM;

EID: 84877703339     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32835cc143     Document Type: Article

References (30)

1. Egeberg O. Inherited Antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965;13:516-530.
2. Koide T, Odani S, Takahashi K, Ono T, Sakuragawa N. Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability. Proc Natl Acad Sci 1984;81:289-293. (Pubitemid 14185715)
3. Lane DA. Antithrombin mutation database. Department of Haematology, Imperial College London, Hammersmith Campus. 2012. http://www1.imperial.ac.uk/ departmentofmedicine/divisions/experimentalmedicine/haematology/coag/ antithrombin/
4. Pavlova A, El-Maarri O, Luxembourg B, Lindhoff-Last E, Kochhan L, Bruhn HD, et al. Detection of heterozygous large deletions in the antithrombin gene using multiplex polymerase chain reaction and denatured high performance liquid chromatography. Haematologica 2006;91:1264-1267. (Pubitemid 44408441)
5. Cooper DN, Ball EV, Stenson PD, Phillips AD, Shaw K, Mort ME. Human Gene Mutation Database. Institute of Medical Genetics, University of Cardiff. 2012. http://www.hgmd.cf.ac.uk/ac/index.php
6. Picard V, Nowak-Göttl U, Biron-Andreani C, Fouassier M, Frere C, Goualt-Heilman M, et al. Molecular bases of antithrombin deficiency: twenty-two novel mutations in the antithrombin gene. Human Mutation 2006;27:600-1600.
7. Beauchamp NJ, Makris M, Preston FE, Peake IR, Daly ME. Major structural defects in the antithrombin gene in four families with type I antithrombin deficiency partial/complete deletions and rearrangement of the antithrombin gene. Thromb Haemost 2000;83:715-721. (Pubitemid 30248520)
8. Luxembourg B, Delev D, Geisen C, Spannagl M, Krause M, Miesbach W, 'et al. Molecular basis of antithrombin deficiency. Thromb Haemost 2011;105:635-646.
9. Olds RJ, Lane DA, Caso R, Panico M, Morris HR, Sas G, et al. Antithrombin III Budapest: a single amino acid substitution (429Pro to Leu) in a region highly conserved in the serpin family. Blood 1992;79:1206-1212.
10. Olds RJ, Lane DA, Boisclair M, Sas G, Bock SC, Thein SL. Antithrombin Budapest 3: an antithrombin variant with reduced heparin affinity resulting from the substitution L99F. FEBS Lett 1992;300:241-246.
11. Kuhle S, Lane DA, Jochmanns K, Male C, Quehenberger P, Lechner K, et al. Homozygous antithrombin deficiency type II (99 Leu to Phe Mutation) and childhood thromboembolism. Thromb Haemost 2001;86:1007-1011. (Pubitemid 32975825)
12. Corral J, Hernandez-Espinosa D, Soria JM, Gonzalez-Conejero R, Ordonez A, Gonzalez-Porras JR, et al. Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood 2007;109:4258-4263. (Pubitemid 46743391)
13. Rossi E, Chiusolo P, Za T, Marietti S, Ciminello A, Leone G, et al. Report of a novel kindred with antithrombin heparin-binding site variant (47 Arg to His): demand for an automated progressive antithrombin assay to detect molecular variants with low thrombotic risk. Thromb Haemost 2007;98:695-697. (Pubitemid 47412904)
14. Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost 1987;58:1094.
15. Wells PS, Blajchman MA, Henderson P, Wells MJ, Demers C, Bourque R, et al. Prevalence of antithrombin deficiency in healthy blood donors: a cross-sectional study. Am J Hematol 1994;45:321-324. (Pubitemid 24109908)
16. Lane DA, Bayston T, Olds RJ, Fitches AC, Cooper DN, Millar DS, et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997;77:197-211. (Pubitemid 27064991)
17. Khalid S, Sajid R, Adil SN, Khurshid M. Frequency of hereditary thrombophilia: an AKUH experience. J Pak Med Assoc 2004;54:427-429. (Pubitemid 39222321)
18. Tait RC, Walker ID, Islam SI, McCall F, Conkie JA, Mitchell R, et al. Influence of demographic factors on antithrombin III activity in a healthy population. Br J Haematol 1993;84:476-480. (Pubitemid 23224165)
19. Lane DA, Kunz G, Olds RJ, Thein SL. Molecular genetics of antithrombin deficiency. Blood Rev 1996;10:59-74. (Pubitemid 26234214)
20. MitsuguroM, Sakata T, Okamoto A, Kameda S, Kokubo Y, Tsutsumi Y, et al. Usefulness of antithrombin deficiency phenotypes for risk assessment of venous thromboembolism: type I deficiency as a strong risk factor for venous thromboembolism. Int J Hematol 2010;92:468-473.
21. Fischer R, Heidinger K, Huth-Kühne A, Staritz P, Zimmermann R, Pavlova A, et al. Antithrombin deficiency: a gap in diagnostics. J Thromb Haemost 2007;5 (Suppl 2):PPMO513.
22. Fischer R, Heidinger K, Blütters-Sawatzki R, Pavlova A, Oldenburg J, Kemkes-Matthes B. A novel antithrombin mutation (g.6566AG;Lys222Arg) causing hereditary antithrombin deficiency in a year old girl. Hämostaseologie 2009;29:A14 (SY/FC15-14).
23. Vossen CY, Conard J, Fontcuberta J, Makris M, van der Meer FJM, Pabinger I, et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost 2005;3:459-464. (Pubitemid 41632870)
24. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999;82:610-619.
25. Blondel-Hill E, Mant MJ. The pregnant antithrombin III deficient patient: management without antithrombin III concentrate. Thromb Res 1992;65:193-198.
26. Perry DJ, Carrell RW. CpG dinucleotides are 'hotspots' for mutation in the antithrombin III gene. Twelve variants identified using the polymerase chain reaction. Mol Biol Med 1989;6:239-243. (Pubitemid 20092737)
27. Daly M, Bruce D, Perry DJ, Price J, Harper PL, O'Meara A, et al. Antithrombin Dublin (-3 Val ! Glu): an N-terminal variant which has an aberrant signal peptidase cleavage site. FEBS Lett 1990;273:87-90.
28. Cooper PC, Coath F, Daly ME, Makris M. The phenotypic and genetic assessment of antithrombin deficiency. Int J Lab Hematol 2011;33:227-237.
29. Demers C, Henderson P, Blajchman MA, Wells MJ, Mitchell L, Johnston M, et al. An antithrombin III assay based on factor xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost 1993;69:231-235. (Pubitemid 23068999)
30. Maecker HT, Lindstrom TM, Robinson WH, Utz PJ, Hale M, Boyd SD, et al. New tools for classification and monitoring of autoimmune diseases. Nat Rev Rheumatol 2012;8:317-328.